Tradestie Institutional Equity Comparison Engine

CLSD vs CHEK โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2025-11-28 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CHEK Overall Edge

CHEK Captures Institutional Edge (2โ€“0 Pillars ยท 6โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Check-Cap Ltd. (CHEK) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, CLSD trades at N/M Forward P/E with -3502.5% operating margin (-80.6% YoY revenue) versus CHEK at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CLSD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CHEK sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CLSD N/M vs CHEK N/M Fwd P/E
Growth & Margin Winner CHEK
Op Margin -3502.5% vs 0.0% ยท YoY -80.6% vs +0.0%
Momentum & Technical Winner CHEK
1Y -97.5% vs +95.8% ยท 52W Pos 1% vs 41%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CLSD NASDAQ
Clearside Biomedical, Inc. Common Stock
Pharmaceutical Preparations
$0.41
-26.96% 1D
Market Cap $2.9M
1M Return -88.86%
1Y Return -97.47%
Forward P/E N/M
Unified AI Score
43.3 / 100 HOLD
Tech 40.0 Fund 43.0 Flow 50.0 Mom 40.0
CHEK NASDAQ
Check-Cap Ltd.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$1.61
+1.9% 1D
Market Cap $9.2M
1M Return +8.05%
1Y Return +95.84%
Forward P/E N/M
Unified AI Score
52.1 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CLSD -97.47% CHEK +95.84% Spread: +193.43 pp (CHEK Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CLSD TTM Op. Margin: -3502.5% CHEK TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLSD vs CHEK. Trailing 12-month operating profitability (CLSD -3502.5% vs CHEK 0.0%) and valuation multiples (CLSD N/M vs CHEK N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CLSD (0) vs CHEK (6)
Institutional Metric CLSD CHEK Criterion Row Winner
Market Capitalization Scale $2.9M $9.2M Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -80.6% +0.0% Higher Growth CHEK
Operating Margin (TTM) Profitability -3502.5% 0.0% Higher Margin CHEK
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -1310.0% -226.2% Higher ROE CHEK
52-Week Range Position Momentum 1% ($0โ€“$17) 41% ($1โ€“$3) Stronger Trend CHEK
Beta / 30D Volatility Risk Regime 2.24ฮฒ ยท 269% Vol 0.94ฮฒ ยท 179% Vol Lower Realized Risk CHEK
Unified Institutional Score Composite Signal 43.3 / 100 (HOLD) 52.1 / 100 (HOLD) Higher Composite CHEK

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CLSD vs CHEK Buy Guide
CLSD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLSD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CHEK UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CHEK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CLSD nor CHEK registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.